HUTCHMED (China) Limited (NASDAQ:HCM – Get Free Report) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 467,900 shares, a decline of 8.1% from the November 30th total of 509,300 shares. Based on an average daily volume of 95,100 shares, the short-interest ratio is presently 4.9 days.
HUTCHMED Stock Up 0.3 %
NASDAQ:HCM traded up $0.05 during midday trading on Wednesday, hitting $14.41. The company had a trading volume of 39,395 shares, compared to its average volume of 114,476. The stock’s fifty day moving average price is $17.05 and its 200-day moving average price is $17.92. HUTCHMED has a 52-week low of $11.93 and a 52-week high of $21.92. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.
Wall Street Analyst Weigh In
Separately, StockNews.com downgraded HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.
Institutional Investors Weigh In On HUTCHMED
A number of hedge funds have recently made changes to their positions in HCM. M&G PLC lifted its stake in shares of HUTCHMED by 98.1% in the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock valued at $5,345,000 after acquiring an additional 132,333 shares during the last quarter. Renaissance Technologies LLC lifted its position in HUTCHMED by 74.8% in the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock valued at $2,248,000 after purchasing an additional 56,200 shares during the last quarter. Jane Street Group LLC boosted its stake in shares of HUTCHMED by 362.2% during the third quarter. Jane Street Group LLC now owns 62,997 shares of the company’s stock valued at $1,305,000 after purchasing an additional 49,366 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of HUTCHMED by 99.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock valued at $952,000 after purchasing an additional 24,245 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in shares of HUTCHMED in the third quarter worth approximately $421,000. 8.82% of the stock is currently owned by institutional investors.
HUTCHMED Company Profile
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Read More
- Five stocks we like better than HUTCHMED
- 3 Healthcare Dividend Stocks to Buy
- Work and Play: Investing in the Rise of Bleisure Travel
- How to Calculate Return on Investment (ROI)
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- How to Find Undervalued Stocks
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.